Harm Reduction Was Built for Opioids. If You Use Meth, You Already Know It Shows.

“I used meth for three or four years, every day, and while it made a lot of things in my life harder I’m not sure how else I could have managed the things it made easier.” That’s Kastalia Medrano, deputy editor at the harm reduction outlet Filter and a former syringe-program peer worker, writing this month about her own daily meth use — including the years it kept her husband functioning through a genuinely brutal decade. She isn’t asking for pity and she isn’t glamorizing it. She’s making an argument: harm reduction services, as built, were designed for people who use opioids and then “retrofitted” for people who use stimulants, and the retrofit shows.

If you use stimulants, the system built to help you was designed for someone else’s drug, someone else’s overdose, someone else’s withdrawal — and you’ve been navigating the gap yourself.

You know this if you’ve ever looked for a program and found naloxone kiosks, buprenorphine referrals, and fentanyl test strips — all genuinely useful, none of them built around what stimulant use actually requires. There’s no FDA-approved medication for stimulant use disorder. There’s no overdose-reversal drug shaped for meth the way naloxone is shaped for opioids. What there is, Medrano argues, is stigma: policing and moral judgment aimed at stimulant users as a supposedly more “erratic” or dangerous population, instead of services built around the actual risks — cardiac strain, sleep deprivation, psychosis risk, and the isolation of using a drug the field still treats as a footnote.

New research gives that felt experience a mechanism. A Yale study published in Nature Mental Health this spring found that moment-to-moment craving physically reshapes how the brain learns from reward — and it does it differently by drug. In plain terms: craving doesn’t just make you want something more, it changes how your brain grades the outcome afterward, warping the internal math your brain uses to decide what’s worth repeating. For cocaine specifically, researchers found craving intensifies how vivid and rewarding the drug cue feels in memory, making the next craving hit harder. The researchers also draw a line between the craving you consciously feel and a second, unconscious kind — meaning relapse can happen without any warning sensation a person could act on, which should reshape how clinicians and peer-support models like AA talk about “triggers” as something a person can always see coming.

None of this required a study to tell Medrano what four years of daily use already taught her. What it does is give clinicians and program designers a harder floor to build from — the next stimulant-specific service doesn’t have to start from a fentanyl-shaped template and hope it fits.